
Woolsey Pharmaceuticals: Innovating treatments for challenging diseases, accelerating global health solutions.
Woolsey Pharmaceuticals, founded in 2019, is dedicated to reinventing treatments for some of the world's most challenging diseases, with a particular focus on neurodegenerative conditions. The company aims to accelerate the delivery of innovative medicines to improve global health outcomes. Headquartered in an undisclosed location, Woolsey Pharmaceuticals offers a range of cutting-edge pharmaceutical products and services designed to push the boundaries of medical science.
Notable figures associated with Woolsey Pharmaceuticals include leading scientists and industry experts who contribute to its pioneering research and development efforts. The company has garnered attention from prominent investors in the biotech sector, enabling it to achieve significant milestones in drug development. Woolsey's impact is marked by its commitment to advancing medical science and providing expanded access to groundbreaking treatments, positioning itself as a key player in the fight against debilitating diseases.

Amylyx Pharmaceuticals
amylyx.com

Chase Therapeutics

Wellesley Pharmaceuticals

Osprey Pharmaceuticals USA
ospreypharma.com

PleoPharma
pleopharma.com

Pharmos
pharmoscorp.com

Aria Pharmaceuticals

Appello Pharmaceuticals
appellopharma.com

Reset Pharmaceuticals

CuraSen Therapeutics
curasen.com

Dose Therapeutics

Visum Pharma
visumpharmainc.com

NeuroTherapeutics Pharma

NeuroPro Therapeutics

Gilgamesh Pharmaceuticals
Companies similar to Woolsey Pharmaceuticals include Amylyx Pharmaceuticals, Chase Therapeutics, Wellesley Pharmaceuticals and Osprey Pharmaceuticals USA.
Woolsey Pharmaceuticals was founded in 2019.
Woolsey Pharmaceuticals' headquarters is located in New York City, NY, US.
Woolsey Pharmaceuticals' most recent funding round was for $19.7M (USD) in October 2021.
As of Oct 15, 2021, Woolsey Pharmaceuticals has raised a total of $28.3M (USD).
Woolsey Pharmaceuticals has 9 employees as of Feb 5, 2024.